Federal Budget 2026–27 — What It Means for Genomics and Precision Medicine

The 2026–27 Federal Budget provides several positive signals for genomics and precision medicine in Australia, particularly across precision oncology, clinical trials, medicines access, digital health and innovation policy.

For InGeNA members, the Budget reflects growing recognition within government that genomics-enabled healthcare is becoming increasingly important to Australia’s future health system, productivity agenda and research translation capability.

However, while the Budget contains several enabling measures, it stops short of a broader national implementation strategy for mainstreaming genomics into routine clinical care.

The result is a Budget that is positive — but incomplete — for the genomics sector.

The Most Significant Genomics Measure: Omico and Precision Oncology

The clearest direct investment for the genomics sector is the Australian Government’s commitment of $71 million over three years to continue the Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program through Omico.

This is an important investment for Australians with advanced and incurable cancers, enabling continued access to comprehensive genomic profiling (CGP) and treatment matching at no cost.

The continuation of the program means more Australians with difficult-to-treat cancers can continue to access genomic testing, precision therapies and clinical trial opportunities based on the biology of their cancer.

As industry has been a major investor and partner in Omico’s national programs, InGeNA welcomes this funding as an important step in sustaining precision oncology capability while enabling transition toward a mainstreamed national program supported through a sustainable federated funding model.

Importantly, the Budget signals continued government support for precision oncology, but it still frames CGP primarily within advanced cancer and clinical trial pathways rather than as routine standard-of-care genomic infrastructure nationally.

Positive Signals Across the Broader Ecosystem

Beyond Omico, the Budget includes several broader measures that are relevant to genomics, personalised medicine and innovation-driven healthcare.

These include:

• $5.9 billion over five years for new and amended PBS listings, including cancer and rare disease therapies
• Additional investment toward Medical Research Future Fund (MRFF) disbursements committing to progressively release the full annual distribution from the Medical Research Future Fund (MRFF), increasing to $1 billion per year by 2030–31.
• Funding for My Health Record operations and sharing-by-default reforms
• Clinical trials reform through the National One Stop Shop initiative
• Venture capital and R&D tax incentive reforms
• TGA regulatory reform and greater use of AI-enabled assessment pathways

Collectively, these measures support parts of the genomics ecosystem — including diagnostics, therapeutics, clinical trials, digital health, AI and data infrastructure.

The Budget also takes initial steps toward implementing the Ambitious Australia: Strategic Examination of Research and Development report. These include establishing a National Resilience and Science Council, reforming the R&D Tax Incentive, expanding venture capital settings, supporting CSIRO and NHMRC capacity, and progressing Australia’s association with Horizon Europe.

For industry, the R&D and venture capital reforms are also important as it signals stronger support for young companies undertaking core experimental R&D and help improve access to patient capital. However, implementation detail will matter. In genomics, essential innovation includes validation, interpretation, curation, regulatory evidence generation, clinical utility studies and implementation research. These activities must be recognised as part of the pathway from discovery to patient benefit.

For member companies operating in precision oncology, genomic diagnostics, bioinformatics, clinical trial services and data platforms, these reforms create meaningful opportunities.

What the Budget Still Does Not Address

Despite these positive measures, the Budget does not fundamentally advance the broader mainstreaming of genomics into clinical care through the national infrastructure and system reforms that are increasingly needed.

Notably, the Budget does not appear to include:

• Universal access pathways for comprehensive genomic profiling
• A National Genomic Test Directory
• National genomic data interoperability infrastructure
• Dedicated genomics workforce investment
• A coordinated national implementation framework for genomic medicine

This means Australia continues to face many of the same implementation challenges:

• Fragmented genomic testing access
• Variation between jurisdictions
• Disconnected digital systems
• Complex reimbursement pathways
• Limited integration of genomics into routine care
• Reliance on pilot and time-limited programs

The genomics sector is increasingly moving beyond the question of whether precision medicine works.

The challenge now is how Australia establishes the governance, funding models, interoperability and policy settings required to scale genomics sustainably and equitably across the healthcare system.

What This Means for InGeNA

For InGeNA, the Budget reinforces the importance of continued national advocacy and cross-sector coordination.

The next phase for the sector is not simply research translation — it is health system implementation.

This includes progressing discussions around:

• Sustainable funding pathways for precision oncology
• Integration of genomics into routine clinical workflows
• National interoperability and genomic data infrastructure
• Coordinated HTA pathways for genomics-enabled technologies
• Alignment between Commonwealth and state systems
• Long-term transition from pilots to mainstream healthcare delivery

The Budget provides encouraging momentum in several areas, particularly precision oncology and enabling innovation policy.

The opportunity now is ensuring Australia builds the broader implementation infrastructure needed to move genomics from isolated programs toward nationally coordinated clinical care.